Catharanthalog
Pharmaceutical compound
From Wikipedia, the free encyclopedia
Catharanthalog (CAG) is a non-hallucinogenic serotonin receptor modulator of the ibogalog group related to the iboga alkaloid catharanthine but with a simplified chemical structure.[1][2] It is known to act as a serotonin 5-HT2A receptor partial agonist.[2] The drug produces analgesic-like effects in a neuropathic pain model in rodents that can be reduced by the serotonin 5-HT2A receptor antagonist ketanserin.[2] Catharanthalog is said to have relatively low blood–brain barrier permeability owing to relatively low lipophilicity.[2] It does not produce the head-twitch response, a behavioral proxy of psychedelic effects, in rodents.[2] The drug was first described in the scientific literature by 2025.[1][2]
- None
| |
 | |
| Clinical data | |
|---|---|
| Other names | CAG |
| Drug class | Non-hallucinogenic serotonin 5-HT2A receptor partial agonist |
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| Chemical and physical data | |
| Formula | C15H18N2O2 |
| Molar mass | 258.321 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
